Camp4 Therapeutics Corp. (CAMP)
Market Closed
12 Dec, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
6. 48
+0.47
+7.82%
$
76.89M Market Cap
- P/E Ratio
0% Div Yield
238,872 Volume
-5.27 Eps
$ 6.01
Previous Close Day Range
5.89 6.6
Year Range
1.3 9.71
Want to track CAMP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CAMP4 Analyst Highlights Rare Disease Platform Potential
In October, CAMP4 Therapeutics Corporation CAMP priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million in gross proceeds.
Benzinga | 1 year ago
Camp4 Therapeutics Targets IPO On Early Positive Results
Camp4 Therapeutics is seeking $75 million in an IPO to fund the advancement of its clinical-stage biopharma programs targeting genetic disorders. CAMP's lead candidate, CMP-CPS-001, has shown positive Phase 1 safety results for treating urea cycle disorders, with no concerning safety trends observed. The urea cycle disorders market is moderate in size, with a low expected growth rate, but Camp4 aims to broaden into larger markets.
Seekingalpha | 1 year ago
2025 © Marketlog. All Rights Reserved.
